Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data

Christopher L.l. Morgan; Paul Emery; Duncan Porter; Alan Reynolds; Adam Young; Helen Boyd; Chris D. Poole; Craig J. Currie

doi:10.1093/rheumatology/ket333

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data

Christopher L.l. Morgan, Paul Emery, Duncan Porter, Alan Reynolds, Adam Young, Helen Boyd, Chris D. Poole, Craig J. Currie

School of Life and Medical Sciences

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

The objective of this study was to examine the long-term safety of etanercept (ETN) in comparison with conventional DMARDs in a large observational cohort of RA patients in the UK.

Original language	English
Pages (from-to)	186-94
Number of pages	9
Journal	Rheumatology
Volume	53
Issue number	1
Early online date	18 Oct 2013
DOIs	https://doi.org/10.1093/rheumatology/ket333
Publication status	Published - Jan 2014

Keywords

Antirheumatic Agents
Arthritis, Rheumatoid
Female
Follow-Up Studies
Forecasting
Great Britain
Humans
Immunoglobulin G
Male
Middle Aged
Prospective Studies
Receptors, Tumor Necrosis Factor
Survival Rate
Treatment Outcome
Tumor Necrosis Factor-alpha

Access to Document

10.1093/rheumatology/ket333

Cite this

@article{5a5011c9ec5f4738b655a850ed19cfdf,

title = "Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data",

abstract = "The objective of this study was to examine the long-term safety of etanercept (ETN) in comparison with conventional DMARDs in a large observational cohort of RA patients in the UK.",

keywords = "Antirheumatic Agents, Arthritis, Rheumatoid, Female, Follow-Up Studies, Forecasting, Great Britain, Humans, Immunoglobulin G, Male, Middle Aged, Prospective Studies, Receptors, Tumor Necrosis Factor, Survival Rate, Treatment Outcome, Tumor Necrosis Factor-alpha",

author = "Morgan, {Christopher L.l.} and Paul Emery and Duncan Porter and Alan Reynolds and Adam Young and Helen Boyd and Poole, {Chris D.} and Currie, {Craig J.}",

year = "2014",

month = jan,

doi = "10.1093/rheumatology/ket333",

language = "English",

volume = "53",

pages = "186--94",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press (OUP)",

number = "1",

}

TY - JOUR

T1 - Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs

T2 - long-term safety and survival using prospective, observational data

AU - Morgan, Christopher L.l.

AU - Emery, Paul

AU - Porter, Duncan

AU - Reynolds, Alan

AU - Young, Adam

AU - Boyd, Helen

AU - Poole, Chris D.

AU - Currie, Craig J.

PY - 2014/1

Y1 - 2014/1

N2 - The objective of this study was to examine the long-term safety of etanercept (ETN) in comparison with conventional DMARDs in a large observational cohort of RA patients in the UK.

AB - The objective of this study was to examine the long-term safety of etanercept (ETN) in comparison with conventional DMARDs in a large observational cohort of RA patients in the UK.

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Female

KW - Follow-Up Studies

KW - Forecasting

KW - Great Britain

KW - Humans

KW - Immunoglobulin G

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Receptors, Tumor Necrosis Factor

KW - Survival Rate

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

U2 - 10.1093/rheumatology/ket333

DO - 10.1093/rheumatology/ket333

M3 - Article

C2 - 24140761

SN - 1462-0324

VL - 53

SP - 186

EP - 194

JO - Rheumatology

JF - Rheumatology

IS - 1

ER -

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data

Abstract

Keywords

Access to Document

Fingerprint

Cite this